You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Triple Combination

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 27, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Duarte (drug, biological, other)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic Triple-Negative Breast Carcinoma
  • Los Angeles, California
    Cedars-Sinai Medical Center
Jan 6, 2023

TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
May 29, 2022

Triple Negative Breast Cancer (TNBC) Trial in United States (Combination of liposomal doxorubicin)

Not yet recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Combination of liposomal doxorubicin
  • Elizabeth, New Jersey
  • +7 more
Jul 13, 2023

Triple-negative Breast Cancer Trial in Shanghai (chidamide, camrelizumab, carboplatin)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2022

Atezolizumab With Nab-paclitaxel for Triple-negative Stage IV

Completed
  • Breast Cancer Metastatic
  • Atezolizumab in combination with nab-paclitaxel
  • Roma, RM, Italy
    Policlinico A. Gemelli - IRCCS
Nov 2, 2022

Triple-Negative Breast Cancer Trial in Taiwan (EndoTAG-1, Paclitaxel, Gemcitabine Hydrochloride)

Suspended
  • Triple-Negative Breast Cancer
  • Kaohsiung, Taiwan
  • +5 more
Dec 6, 2022

Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer Trial in Changsha, Xiangyang (AK117,

Recruiting
  • Metastatic Triple-negative Breast Cancer
  • Locally Advanced Triple-negative Breast Cancer
  • Changsha, China
  • +1 more
Sep 8, 2022

Locally Advanced Solid Tumor Trial in United States (AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection)

Recruiting
  • Locally Advanced Solid Tumor
  • Aurora, Colorado
  • +3 more
Feb 16, 2022

Breast Cancer Trial in Boston (Atezolizumab, Stereotactic radiosurgery (SRS))

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 15, 2022

Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer Trial in Austin, San Antonio, Fairfax (BDC-3042,

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Austin, Texas
  • +2 more
Sep 19, 2023

Triple Negative Breast Cancer, Metastatic Breast Cancer Trial in Boston (Pembrolizumab, PVX-410)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Metastatic Breast Cancer
  • Boston, Massachusetts
  • +2 more
Dec 21, 2022

Metastatic Breast Cancer Trial in Shanghai (Sitravatinib, Tislelizumab, Nab-paclitaxel)

Recruiting
  • Metastatic Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer
Jul 31, 2022

Triple Negative Breast Cancer, Brain Metastases Trial in Saint Louis (Pembrolizumab, Liposomal Irinotecan)

Recruiting
  • Triple Negative Breast Cancer
  • Brain Metastases
  • Saint Louis, Missouri
    Washington University School of Medicine
Jun 1, 2022

Ovarian Cancer, Melanoma, Triple Negative Breast Cancer Trial (NM1F Injection, Pembrolizumab injection)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • NM1F Injection
  • Pembrolizumab injection
  • (no location specified)
Feb 23, 2023

Advanced Cancer, Advanced Malignancies, Bladder Cancer Trial (AB598, Zimberelimab, Carboplatin)

Not yet recruiting
  • Advanced Cancer
  • +11 more
  • (no location specified)
May 26, 2023

Advanced Solid Tumor, Triple Negative Breast Cancer Trial (Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II))

Not yet recruiting
  • Advanced Solid Tumor
  • Triple Negative Breast Cancer
  • Pembrolizumab & ADG106 (Phase Ib)
  • Pembrolizumab & ADG106 (Phase II)
  • (no location specified)
Aug 5, 2022

Type 2 Diabetes Trial in Seongnam (Sitagliptin, Dapagliflozin, Lobeglitazone)

Completed
  • Type 2 Diabetes
  • Seongnam, Gyeonggi, Korea, Republic of
    Soo Lim
Jan 2, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Boston, Galveston,

Suspended
  • Advanced Malignant Solid Neoplasm
  • +4 more
  • Boston, Massachusetts
  • +2 more
Oct 5, 2022

Triple Combination Therapy in Severe Cystic Fibrosis Disease.

Completed
  • Cystic Fibrosis
  • Triple combination therapy
  • Denver, Colorado
    National Jewish Health
Mar 9, 2021

Triple Negative Breast Cancer (TNBC) Trial in China (B013+Nab-Paclitaxel)

Recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Guangzhou, Guangdong, China
  • +6 more
Jan 29, 2023

Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma Trial in Boston (Onvansertib, Paclitaxel)

Recruiting
  • Breast Cancer
  • +9 more
  • Boston, Massachusetts
  • +2 more
Oct 25, 2022

TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial (Pembrolizumab, Radiation Therapy, Axatilimab)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Breast Cancer
  • (no location specified)
Aug 4, 2022

Metastatic Triple-Negative Breast Carcinoma Trial (PVX-410)

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • (no location specified)
Apr 18, 2022

Triple Negative Breast Cancer, Chemo Effect, Simvastatin Adverse Reaction Trial in Jakarta Pusat (Simvastatin 40mg, Placebo)

Recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Simvastatin 40mg
  • Placebo
  • Jakarta Pusat, DKI Jakarta, Indonesia
    Dr. Cipto Mangunkusumo National Central General Hospital
Sep 22, 2022